Lv4
748 积分 2024-01-16 加入
Abstract PO1-06-10: Overall survival results from EVER-132-001, a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer
1天前
求助中
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
21天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
21天前
已关闭
靶向HER2乳腺癌诊疗中国专家共识2025版要点解读
26天前
已关闭
Pulmonary Hypertension Associated With Left Heart Disease: Challenges, Emerging Strategies, and Future Directions
26天前
已完结
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression
1个月前
已完结
靶向HER2乳腺癌诊疗中国专家共识2025版要点解读
1个月前
已关闭
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors
1个月前
已完结
Menopausal hormone treatment and breast cancer
2个月前
已关闭
Therapeutic Considerations in Early-Stage, Estrogen Receptor-Positive, BRCA-Associated Breast Cancer
2个月前
已关闭
皖公网安备34019202002308
